Search Contact
Learn more about our probiotics
with exclusive mechanisms of action

Discover our
clinical research

Neuropharmagen is a precision medicine
tool especially developed for psychiatry

AB-Biotics closes an agreement with INIA to develop probiotic strains
The CEOs of AB-Biotics, Miquel Àngel Bonachera and Sergi Audivert, have signed an agreement with the director of the National Institute of Agricultural and Food Technology...
Read More
Patients with mental health problems treated with Neurofarmagen experience a reduction in adverse effects and respond to treatment quicker and more effectively
The Christmas holidays that have just passed were a cause for celebration for many people, but for many others it could have contributed to the worsening...
Read More
The Company’s Board of Directors agreed to the delisting of all the shares from the Alternative Stock Market
On November 22nd, the Company’s Board of Directors agreed to the delisting of all the shares representing the capital stock of AB-BIOTICS, SA from the Alternative Stock Market, as well as the delegation of powers in favour of the Executive Directors to the aforementioned effects, so that they may act on behalf of and in representation of the Company to execute actions and sign documents, public...
Read More
About ab-biotics
Research in its own
collection of more than
1.000 strains of
probiotic bacteria
Development of
advanced genetic tools
for pharmacogenetics
Precision medicine